Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease

References

• Cohen AT, Agnelli G, Anderson FA et al.; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98(4), 756–764 (2007).
   PubMed Web of Science ®Google Scholar
• Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA; GRACE and GRACE2 Investigators. The Global Registry of Acute Coronary Events, 1999 to 2009 – GRACE. Heart 96(14), 1095–1101 (2010).
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ et al.; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 42(1), 227–276 (2011).
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125(1), e2–e220 (2012).
   PubMed Web of Science ®Google Scholar
• Heit JA, Cohen AT, Anderson FA; The VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 106(11), Abstract 910 (2005).
   Google Scholar
• Rosamond W, Flegal K, Furie K et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N. Engl. J. Med. 362(23), 2155–2165 (2010).
   PubMed Web of Science ®Google Scholar
• Hamm CW, Bassand JP, Agewall S et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA et al.; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e278S–e325S (2012).
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ et al.; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e419S–e494S (2012).
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e531S–e575S (2012).
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e24S–e43S (2012).
   PubMed Web of Science ®Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e44S–e88S (2012).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3(3), 514–521 (2005).
   PubMed Web of Science ®Google Scholar
• Depasse F, Busson J, Mnich J et al. Effect of BAY 59-7939 – a novel, oral, direct Factor Xa inhibitor – on clot-bound Factor Xa activity in vitro. J. Thromb. Haemost. 3(Suppl. 1), Abstract P1104 (2005).
   Google Scholar
• Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78(4), 412–421 (2005).
   PubMed Web of Science ®Google Scholar
• Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 10(1), 61–75 (2011).
   PubMed Web of Science ®Google Scholar
• Xarelto® (rivaroxaban) Summary of Product Characteristics. Bayer Pharma AG, Leverkusen, Germany (2013).
   Google Scholar
• Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 37(5), 1056–1064 (2009).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61(12), 873–880 (2005).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin. 24(10), 2757–2765 (2008).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol. 47(2), 218–226 (2007).
   PubMed Web of Science ®Google Scholar
• Zhao X, Sun P, Zhou Y et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br. J. Clin. Pharmacol. 68(1), 77–88 (2009).
   PubMedGoogle Scholar
• Jiang J, Hu Y, Zhang J et al. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb. Haemost. 103(1), 234–241 (2010).
   PubMedGoogle Scholar
• Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol. 70(5), 703–712 (2010).
   PubMed Web of Science ®Google Scholar
• Halabi A, Kubitza D, Zuehlsdorf M et al. Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 5(Suppl. 2), Abstract P-M-635 (2007).
   Google Scholar
• Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban – an oral, direct factor Xa inhibitor – are not affected by aspirin. J. Clin. Pharmacol. 46(9), 981–990 (2006).
   PubMed Web of Science ®Google Scholar
• Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban – a novel, oral, direct Factor Xa inhibitor – and atorvastatin. Pathophysiol. Haemost. Thromb. 36(Suppl. 1), A40, Abstract P062 (2008).
   Google Scholar
• Kubitza D, Becka M, Mueck W, Schwers S. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a Phase I study. Pharmaceuticals 5, 279–296 (2012).
   Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, Mueck W. No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J. Clin. Pharmacol. 46(6), 702, Abstract 11 (2006).
   Google Scholar
• Kubitza D, Becka M, Voith B, Zuehlsdorf M. Effect of enoxaparin on the safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3(Suppl. 1), Abstract P1704 (2005).
   Google Scholar
• Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) – an oral, direct factor Xa inhibitor – has no clinically relevant interaction with naproxen. Br. J. Clin. Pharmacol. 63(4), 469–476 (2007).
   PubMed Web of Science ®Google Scholar
• Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br. J. Clin. Pharmacol. doi: 10.1111/bcp.12075 (2013) (Epub ahead of print) .
   Google Scholar
• Eriksson BI, Borris LC, Friedman RJ et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358(26), 2765–2775 (2008).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358(26), 2776–2786 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676), 1673–1680 (2009).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Fisher WD, Bauer KA et al.; OdiXa-Knee Study Group. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A Phase II dose-ranging study. J. Thromb. Haemost. 3(11), 2479–2486 (2005).
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Dahl OE et al.; ODIXa-HIP Study Investigators. A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114(22), 2374–2381 (2006).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Eriksson BI et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 105(3), 444–453 (2011).
   PubMed Web of Science ®Google Scholar
• Haas S, Turpie AGG, Jamal W et al. XAMOS: a large non-interventional study in patients undergoing major hip or knee surgery and receiving oral rivaroxaban or conventional regimens for thromboprophylaxis. Presented at: 22nd International Congress on Thrombosis. Nice, France, 6–9 October 2012.
   Google Scholar
• Turpie AGG, Jamal W, Schmidt A et al. XAMOS: a non-interventional study comparing oral rivaroxaban with conventional regimens for thromboprophylaxis after major orthopaedic surgery of the hip and knee. Br. J. Haematol. 157(Suppl. 1), 9, Abstract 20 (2012).
   Google Scholar
• Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombolysis 31(4), 407–416 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Büller HR et al.; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368(6), 513–523 (2013).
   PubMed Web of Science ®Google Scholar
• The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363(26), 2499–2510 (2010).
   PubMed Web of Science ®Google Scholar
• The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of pulmonary embolism. N. Engl. J. Med. 366(14), 1287–1297 (2012).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116(2), 180–187 (2007).
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH et al.; Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112(6), 2242–2247 (2008).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159(3), 340–347 (2010).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR et al.; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 11(4), 315–322 (2012).
   PubMed Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32(19), 2387–2394 (2011).
   PubMed Web of Science ®Google Scholar
• Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet. 50(10), 675–686 (2011).
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R et al.; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33(21), 2719–2747 (2012).
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366(1), 9–19 (2012).
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S et al.; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet 374(9683), 29–38 (2009).
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): Xarelto, rivaroxaban. (2013).
   Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361(6), 594–604 (2009).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717), 807–815 (2010).
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363(26), 2487–2498 (2010).
   PubMed Web of Science ®Google Scholar
• Decousus H, Tapson VF, Bergmann JF et al.; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139(1), 69–79 (2011).
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Leizorovicz A, Kakkar AK et al.; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365(23), 2167–2177 (2011).
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361(24), 2342–2352 (2009).
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Schellong SM et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood (ASH Annual Meeting Abstracts) 118, Abstract 205 (2011).
   Google Scholar
• Schulman S, Eriksson H, Goldhaber SZ et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J. Thromb. Haemost. 9(Suppl. 2), 731, Abstract O-TH-033 (2011).
   Google Scholar
• Schulman S, Baanstra D, Eriksson H et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J. Thromb. Haemost. 9(Suppl. 2), 22, Abstract O-MO-037 (2011).
   Google Scholar
• Agnelli G, Buller HR, Cohen A et al. Two doses of apixaban for the extended treatment of venous thromboembolism. Presented at: American Society of Hematology 54th Annual Meeting and Exposition. GA, USA, 8–11 December 2012.
   Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365(8), 699–708 (2011).
   PubMed Web of Science ®Google Scholar